Increased serum cell-free DNA levels in relation to inflammation are predictive of distant metastasis of esophageal squamous cell carcinoma

Tomochika,Shinobu; Iizuka,Norio; Watanabe,Yusaku; Tsutsui,Masahito; Takeda,Shigeru; Yoshino,Shigefumi; Ichihara,Kiyoshi; Oka,Masaaki

doi:10.3892/etm_00000016

Increased serum cell-free DNA levels in relation to inflammation are predictive of distant metastasis of esophageal squamous cell carcinoma

Authors:
- Shinobu Tomochika
- Norio Iizuka
- Yusaku Watanabe
- Masahito Tsutsui
- Shigeru Takeda
- Shigefumi Yoshino
- Kiyoshi Ichihara
- Masaaki Oka
View Affiliations

Affiliations: Department of Surgery II, Faculty of Health Science, Yamaguchi University Graduate School of Medicine, Yamaguchi 755-8505, Japan
Published online on: January 1, 2010 https://doi.org/10.3892/etm_00000016
Pages: 89-92

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Distant metastasis hinders a favorable outcome for patients with esophageal squamous cell carcinoma (ESCC) by limiting the surgical cure. The levels of cell-free DNA (cfDNA) in the blood have served as a predictor for metastasis and recurrence in distant organs in liver cancer. Thus, this study tested the clinical efficacy of serum cfDNA levels as a predictive marker for distant metastasis of ESCC. We investigated cfDNA levels in a cohort of 101 ESCC patients and 46 age- and gender-matched control patients with benign disease. We found that serum cfDNA levels were significantly higher in the ESCC patients than in the control patients (P=0.034). In the ESCC patients, serum cfDNA levels were positively associated with tumor size and cytokeratin 19 fragment (CYFRA 21-1) expression (r=0.416 and r=0.573, respectively). An increase in cfDNA levels was also associated with host inflammation status including C-reactive protein levels and neutrophil and monocyte numbers in the peripheral blood. Serum cfDNA levels tended to be higher in advanced tumors when compared to early stage tumors. We found that serum cfDNA levels were significantly higher in ESCC patients with distant metastasis than in those without (P=0.011). Logistic regression analysis showed that serum cfDNA levels represented only one independent risk factor for distant metastasis among the five factors tested including gender, age, cfDNA levels, CYFRA 21-1 and squamous cell carcinoma antigen levels (P=0.0414). These results suggest that increased serum cfDNA levels may serve as a useful predictor for distant metastasis of ESCC.

View Figures

View References

1.	Parkin DM, Bray F, Ferlay J and Pisani P: Global cancer statistics. CA Cancer J Clin. 55:74–108. 2005. View Article : Google Scholar
2.	Enzinger PC and Mayer RJ: Esophageal cancer. N Engl J Med. 349:2241–2252. 2003. View Article : Google Scholar : PubMed/NCBI
3.	Oka M, Yamamoto K, Takahashi M, Hakozaki M, Abe T, Iizuka N, Hazama S, Hirazawa K, Hayashi H, Tangoku A, Hirose K, Ishihara T and Suzuki T: Relationship between serum levels of interleukin 6, various disease parameters and malnutrition in patients with esophageal squamous cell carcinoma. Cancer Res. 56:2776–2780. 1996.PubMed/NCBI
4.	Iizuka N, Hirose K, Noma T, Hazama S, Tangoku A, Hayashi H, Abe T, Yamamoto K and Oka M: The nm23-H1 gene as a predictor of sensitivity to chemotherapeutic agents in oesophageal squamous cell carcinoma. Br J Cancer. 81:469–475. 1999. View Article : Google Scholar : PubMed/NCBI
5.	Ishikura S, Nihei K, Ohtsu A, Boku N, Hironaka S, Mera K, Muto M, Ogino T and Yoshida S: Long-term toxicity after definitive chemoradiotherapy for squamous cell carcinoma of the thoracic esophagus. J Clin Oncol. 21:2697–2702. 2003. View Article : Google Scholar : PubMed/NCBI
6.	Kleinberg L and Forastiere AA: Chemoradiation in the management of esophageal cancer. J Clin Oncol. 25:4110–4117. 2007. View Article : Google Scholar : PubMed/NCBI
7.	Chen G, Wang Z, Liu XY, Zhang MY and Liu FY: Abdominal lymph node metastasis in patients with mid thoracic esophageal squamous cell carcinoma. World J Surg. 33:278–283. 2009. View Article : Google Scholar : PubMed/NCBI
8.	Shimada H, Okazumi S, Matsubara H, Nabeya Y, Shiratori T, Shimizu T, Shuto K, Hayashi H and Ochiai T: Impact of the number and extent of positive lymph nodes in 200 patients with thoracic esophageal squamous cell carcinoma after three-field lymph node dissection. World J Surg. 30:1441–1449. 2006. View Article : Google Scholar : PubMed/NCBI
9.	Montesano R, Hollstein M and Hainaut P: Genetic alterations in esophageal cancer and their relevance to etiology and pathogenesis: a review. Int J Cancer. 3:225–235. 1996. View Article : Google Scholar : PubMed/NCBI
10.	Parkin DM, Bray F, Ferlay J and Pisani P: Estimating the world cancer burden: Globocan 2000. Int J Cancer. 94:153–156. 2001. View Article : Google Scholar : PubMed/NCBI
11.	Gautschi O, Bigosch C, Huegli B, Jermann M, Marx A, Chasse E, Ratschiller D, Weder W, Joerger M, Betticher DC, Stahel RA and Ziegler A: Circulating deoxyribonucleic acid as prognostic marker in non-small cell lung cancer patients undergoing chemotherapy. J Clin Oncol. 22:4157–4164. 2004. View Article : Google Scholar : PubMed/NCBI
12.	Tokuhisa Y, Iizuka N, Sakaida I, Moribe T, Fujita N, Miura T, Tamatsukuri S, Ishitsuka H, Uchida K, Terai S, Sakamoto K, Tamesa T and Oka M: Circulating cell-free DNA as a predictive marker for distant metastasis of hepatitis C virus-related hepatocellular carcinoma. Br J Cancer. 97:1399–1403. 2007. View Article : Google Scholar : PubMed/NCBI
13.	Umetani N, Giuliano AE, Hiramatsu SH, Amersi F, Nakagawa T, Martino S and Hoon DS: Prediction of breast tumor progression by integrity of free circulating DNA in serum. J Clin Oncol. 24:4270–4276. 2006. View Article : Google Scholar : PubMed/NCBI
14.	Tomita H, Ichikawa D, Ikoma D, Sai S, Tani N, Ikoma H, Fujiwara H, Kikuchi S, Okamoto K, Ochiai T and Otsuji E: Quantification of circulating plasma DNA fragments as tumor markers in patients with esophageal cancer. Anticancer Res. 27:2737–2741. 2007.
15.	Sobin LH and Wittekind C: TNM Classification of Malignant Tumours. 6th edition. UICC, Wiley-Liss; pp. 81–83. 2002
16.	Iizuka N, Sakaida I, Moribe T, Fujita N, Miura T, Stark M, Tamatsukuri S, Ishitsuka H, Uchida K, Terai S, Sakamoto K, Tamesa T and Oka M: Elevated levels of circulating cell-free DNA in the blood of patients with hepatitis C virus-associated hepatocellular carcinoma. Anticancer Res. 26:4713–4719. 2006.PubMed/NCBI
17.	Balkwill F and Mantovani A: Inflammation and cancer: back to Virchow? Lancet. 357:539–545. 2001. View Article : Google Scholar : PubMed/NCBI
18.	Iida M, Iizuka N, Sakaida I, Moribe T, Fujita N, Miura T, Tamatsukuri S, Ishitsuka H, Uchida K, Terai S, Tokuhisa Y, Sakamoto K, Tamesa T, Miyamoto T, Hamamoto Y and Oka M: Relation between serum levels of cell-free DNA and inflammation status in hepatitis C virus-related hepatocellular carcinoma. Oncol Rep. 20:761–765. 2008.PubMed/NCBI
19.	Barak V, Goike H, Panaretakis KW and Einarsson R: Clinical utility of cytokeratins as tumor markers. Clin Biochem. 37:529–540. 2004. View Article : Google Scholar : PubMed/NCBI
20.	Yamamoto K, Oka M, Hayashi H, Tangoku A, Gondo T and Suzuki T: CYFRA 21-1 is a useful marker for esophageal squamous cell carcinoma. Cancer. 79:1647–1655. 1997. View Article : Google Scholar : PubMed/NCBI
21.	Brockmann JG, St Nottberg H, Glodny B, Heinecke A and Senninger NJ: CYFRA 21-1 serum analysis in patients with esophageal cancer. Clin Cancer Res. 6:4249–4252. 2000.PubMed/NCBI